The treatment with both drugs in combination induced synergistic or additive effects in del(17p) cells, suggesting that PRIMA-1 enhanced the cytotoxicity of fludarabine in CLL cells with a P53 dysfunction [69]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.